Advaxis has recently announced an agreement with Amgen for the development and commercialisation of its preclinical asset ADXS-NEO (Deal no. 72608). Under the terms of the agreement, Amgen will make an upfront payment of US$40 M and purchase US$25 M of Advaxis stock, with Amgen also fully funding clinical and commercial activities related to ADXS-NEO. Advaxis will still be responsible for proof-of-concept studies and manufacturing. Advaxis will also be eligible to receive milestone payments of up to US$475 M and up to mid-double digit royalties of worldwide sales should ADXS-NEO make it to market.